Innate Pharma S.A. (IPH.PA)

EUR 1.98

(-3.37%)

Total Liabilities Summary of Innate Pharma S.A.

  • Innate Pharma S.A.'s latest annual total liabilities in 2023 was 132.29 Million EUR , down -13.94% from previous year.
  • Innate Pharma S.A.'s latest quarterly total liabilities in 2024 Q1 was 122.7 Million EUR , down -7.25% from previous quarter.
  • Innate Pharma S.A. reported annual total liabilities of 153.71 Million EUR in 2022, down -3.96% from previous year.
  • Innate Pharma S.A. reported annual total liabilities of 160.05 Million EUR in 2021, up 5.68% from previous year.
  • Innate Pharma S.A. reported quarterly total liabilities of 122.7 Million EUR for 2024 Q2, down 0.0% from previous quarter.
  • Innate Pharma S.A. reported quarterly total liabilities of 132.29 Million EUR for 2023 Q3, down -6.3% from previous quarter.

Annual Total Liabilities Chart of Innate Pharma S.A. (2023 - 2005)

Historical Annual Total Liabilities of Innate Pharma S.A. (2023 - 2005)

Year Total Liabilities Total Liabilities Growth
2023 132.29 Million EUR -13.94%
2022 153.71 Million EUR -3.96%
2021 160.05 Million EUR 5.68%
2020 151.44 Million EUR -17.67%
2019 183.94 Million EUR -35.23%
2018 283.97 Million EUR 67.97%
2017 169.06 Million EUR -13.48%
2016 195.4 Million EUR -16.45%
2015 233.88 Million EUR 1355.98%
2014 16.06 Million EUR 3.0%
2013 15.59 Million EUR -37.44%
2012 24.93 Million EUR -25.54%
2011 33.48 Million EUR 131.02%
2010 14.49 Million EUR -15.22%
2009 17.09 Million EUR -12.42%
2008 19.52 Million EUR 44.1%
2007 13.54 Million EUR 5.13%
2006 12.88 Million EUR 174.05%
2005 4.7 Million EUR 0.0%

Peer Total Liabilities Comparison of Innate Pharma S.A.

Name Total Liabilities Total Liabilities Difference
ABIONYX Pharma SA 6.91 Million EUR -1813.947%
ABIVAX Société Anonyme 131.05 Million EUR -0.946%
Adocia SA 31.87 Million EUR -315.099%
Aelis Farma SA 13.08 Million EUR -911.407%
Biophytis S.A. 15.84 Million EUR -734.703%
Advicenne S.A. 24.37 Million EUR -442.692%
genOway Société anonyme 14.45 Million EUR -814.913%
IntegraGen SA 5.97 Million EUR -2112.316%
Medesis Pharma S.A. 6.42 Million EUR -1958.64%
Neovacs S.A. 3.71 Million EUR -3463.782%
NFL Biosciences SA 3.62 Million EUR -3553.786%
Plant Advanced Technologies SA 6.78 Million EUR -1850.533%
Quantum Genomics Société Anonyme 3.31 Million EUR -3896.608%
Sensorion SA 13.22 Million EUR -900.146%
Theranexus Société Anonyme 5.01 Million EUR -2537.301%
TME Pharma N.V. 2.78 Million EUR -4650.162%
Valbiotis SA 13.7 Million EUR -865.071%
TheraVet SA 1.48 Million EUR -8808.594%
Valerio Therapeutics Société anonyme 20.46 Million EUR -546.336%
argenx SE 402.79 Million EUR 67.157%
BioSenic S.A. 32.26 Million EUR -310.03%
Celyad Oncology SA 9.97 Million EUR -1225.837%
DBV Technologies S.A. 38.74 Million USD -241.44%
Galapagos NV 1.56 Billion EUR 91.53%
Genfit S.A. 105.92 Million EUR -24.897%
GeNeuro SA 20.13 Million EUR -556.865%
Hyloris Pharmaceuticals SA 8.61 Million EUR -1436.136%
Inventiva S.A. 101.59 Million EUR -30.218%
MaaT Pharma SA 22.46 Million EUR -488.88%
MedinCell S.A. 77.77 Million EUR -70.107%
Nanobiotix S.A. 95.74 Million EUR -38.178%
Onward Medical N.V. 25.69 Million EUR -414.795%
Oryzon Genomics S.A. 25.12 Million EUR -426.525%
OSE Immunotherapeutics SA 59.07 Million EUR -123.924%
Oxurion NV 19.73 Million EUR -570.308%
Pharming Group N.V. 228.28 Million EUR 42.05%
Poxel S.A. 53.9 Million EUR -145.435%
GenSight Biologics S.A. 34.72 Million EUR -280.949%
Transgene SA 26.51 Million EUR -398.895%
Financière de Tubize SA 123.65 Million EUR -6.989%
UCB SA 6.56 Billion EUR 97.985%
Valneva SE 341.14 Million EUR 61.221%
Vivoryon Therapeutics N.V. 4.54 Million EUR -2809.435%